Association of medically assisted reproduction with offspring cord blood DNA methylation across cohorts

Doretta Caramaschi1,2,*, James Jungius1,2, Christian M. Page3,4, Boris Novakovic5,6, Richard Saffery7,5,6, Jane Halliday5,6, Sharon Lewis5,6, Maria C. Magnus1,2,4, Stephanie J. London7, Siri E. Ha˚berg8, Caroline L. Relton1,2, Deborah A. Lawlor1,2,8, and Hannah R. Elliott1,2

1MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK 2Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK 3Division for Research Support, Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway 4Centre for Fertility and Health, Norwegian Institute of Health, Oslo, Norway 5Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, VIC, Australia 6Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia 7Department of Health and Human Services, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA 8Bristol NIHR Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, Bristol, UK

*Correspondence address. MRC Integrative Epidemiology Unit, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK. Tel: +44-117-331-4018; E-mail: D.Caramaschi@bristol.ac.uk

Submitted on June 18, 2020; resubmitted on April 16, 2021; editorial decision on April 27, 2021

STUDY QUESTION: Is cord blood DNA methylation associated with having been conceived by medically assisted reproduction?

SUMMARY ANSWER: This study does not provide strong evidence of an association of conception by medically assisted reproduction with variation in infant blood cell DNA methylation.

WHAT IS KNOWN ALREADY: Medically assisted reproduction consists of procedures used to help infertile/subfertile couples conceive, including ART. Due to its importance in gene regulation during early development programming, DNA methylation and its perturbations associated with medically assisted reproduction could reveal new insights into the biological effects of assisted reproductive technologies and potential adverse offspring outcomes.

STUDY DESIGN, SIZE, DURATION: We investigated the association of DNA methylation and medically assisted reproduction using a case–control study design (N = 205 medically assisted reproduction cases and N = 2439 naturally conceived controls in discovery cohorts; N = 149 ART cases and N = 58 non-ART controls in replication cohort).

PARTICIPANTS/MATERIALS, SETTINGS, METHODS: We assessed the association between medically assisted reproduction and DNA methylation at birth in cord blood (205 medically assisted conceptions and 2439 naturally conceived controls) at >450 000 CpG sites across the genome in two sub-samples of the UK Avon Longitudinal Study of Parents and Children (ALSPAC) and two sub-samples of the Norwegian Mother, Father and Child Cohort Study (MoBa) by meta-analysis. We explored replication of findings in the Australian Clinical review of the Health of adults conceived following Assisted Reproductive Technologies (CHART) study (N = 149 ART conceptions and N = 58 controls).

MAIN RESULTS AND THE ROLE OF CHANCE: The ALSPAC and MoBa meta-analysis revealed evidence of association between conception by medically assisted reproduction and DNA methylation (false-discovery-rate-corrected P-value < 0.05) at five CpG sites which are annotated to two genes (percentage difference in methylation per CpG, cg24051276: Beta = 0.23 (95% CI 0.15,0.31); cg00012522: Beta = 0.47 (95% CI 0.31, 0.63); cg17855264: Beta = 0.31 (95% CI 0.20, 0.43); cg17132421: Beta = 0.30 (95% CI 0.18, 0.42); cg18529845: Beta = 0.41 (95% CI 0.25, 0.57)). Methylation at three of these sites has been previously linked to cancer, aging, HIV infection and neurological diseases. None of these associations replicated in the CHART cohort. There was evidence of a functional role
of medically assisted reproduction-induced hypermethylation at CpG sites located within regulatory regions as shown by putative transcription factor binding and chromatin remodelling.

**LIMITATIONS, REASONS FOR CAUTIONS:** While insufficient power is likely, heterogeneity in types of medically assisted reproduction procedures and between populations may also contribute. Larger studies might identify replicable variation in DNA methylation at birth due to medically assisted reproduction.

**WIDER IMPLICATIONS OF THE FINDINGS:** Newborns conceived with medically assisted procedures present with divergent DNA methylation in cord blood white cells. If these associations are true and causal, they might have long-term consequences for offspring health.

**STUDY FUNDING/COMPETING INTEREST(S):** This study has been supported by the US National Institute of Health (R01 DK10324), the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007-2013)/ERC Grant agreement no. 669545, European Union’s Horizon 2020 research and innovation programme under Grant agreement no. 733206 (LifeCycle) and the NIHR Biomedical Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. Methylation data in the ALSPAC cohort were generated as part of the UK BBSRC funded (BB/102571/1 and BB/102526/1) Accessible Resource for Integrated Epigenomic Studies (ARIES, http://www.ariseauk.org.uk). D.C., J.J., C.L.R. D.A.L. and H.R.E. work in a Unit that is supported by the University of Bristol and the UK Medical Research Council (Grant nos. MC_UU_00011/1, MC_UU_00011/5 and MC_UU_00011/6). B.N. is supported by an NHMRC (Australia) Investigator Grant (1173314). ALSPAC GWAS data were generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research, NIH/NIEHS (Contract no. N01-ES-75558), NIH/NINIDS (Grant nos. (i) U01 NS 047537-01 and (ii) U01 NS 047537-06A1). For this work, MoBa 1 and 2 were supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES-49019) and the Norwegian Research Council/BIOBANK (Grant no. 221097). This work was partly supported by the Research Council of Norway through its Centres of Excellence funding scheme, Project no. 262700. D.A.L. has received support from national and international government and charity funders, as well as from Roche Diagnostics and Medtronic for research unrelated to this study. The other authors declare no conflicts of interest.

**TRIAL REGISTRATION NUMBER:** N/A.

**Key words:** assisted reproductive technology / medically assisted reproduction / IVF / DNA methylation / epigenetics / ALSPAC / MoBa / CHART

---

### Introduction

The number of children conceived using ART has increased steadily over the last four decades. ART include any treatment that consists of in vitro handling of human sperm, oocytes and embryos such as IVF/ICSI and gamete and embryo cryopreservation. More broadly, medically assisted reproduction refers to any treatment/intervention for fertility impairment and infertility, including ART and other procedures such as ovulation induction (OI) and intrauterine insemination that might use hormones to stimulate oocyte production but do not usually handle gametes (Zegers-Hochschild et al., 2017). The timing of developmental epigenetic reprogramming coinciding with fertility interventions and the susceptibility of DNA methylation to environmental stresses have led to suggestions that fertility interventions may alter the offspring’s DNA methylation patterns (Canovas et al., 2017). Alterations in the embryo demethylation and re-methylation processes due to medically assisted reproduction can be caused by nutritional stress due to in vitro culture conditions, hormonal overstimulation of the ovary beyond the physiological range due to superovulation-inducing procedures, or a combination of the two exposures (Doherty et al., 2000; Mann et al., 2004; Market-Velker et al., 2010a, 2010b; Market-Velker et al., 2012; White et al., 2015; Velker et al., 2017). Medically assisted reproduction procedures may subject gametes and early embryos to environmental stress which may impact the development of the foetus, for example, by disruptions in the expression of imprinted genes (Sakian et al., 2015). Gamete and embryo cryopreservation methods can also affect DNA methylation (Van Heertum and Weinerman, 2018; Cao et al., 2019).

Earlier studies investigating the association of ART and DNA methylation at birth have focused on imprinted genes and found mixed results which overall point to weak evidence of any association when meta-analyzed (Lazaravicute et al., 2014). Other studies have included other non-imprinted candidate genes, resulting in the discovery of some associations between treatment and methylation in cord blood and placental cells (Katari et al., 2009; Tierling et al., 2010; Song et al., 2015). More recent studies have moved from a candidate gene to a genome-wide analysis approach. Some genome-wide studies have identified differential methylation in neonatal blood cells between ART (or, more specifically, IVF) and controls (Melamed et al., 2015; Estill et al., 2016; Castillo-Fernandez et al., 2017; El Hajj et al., 2017; Novakovic et al., 2019). However, other similar studies have found little evidence (Gentilini et al., 2018; Choufani et al., 2019), perhaps owing to small sample sizes, comparisons with different procedures across some studies and consequently insufficient power to detect true associations. Only one study has included more than 100 conceptions through ART (Novakovic et al., 2019), and, although it found several associations, it did not control for potential confounding from parental characteristics.

Whilst different ART procedures have been associated with a wide range of adverse perinatal and longer-term offspring outcomes (Kallen et al., 2010; Hansen et al., 2013; Chen and Heilbronn, 2017; Elias et al., 2020), a large recent study with follow-up to 22–35 years, did
not confirm the associations with longer-term outcomes (Halliday et al., 2019). Moreover, the extent to which any associations with adverse outcomes are related to multiple pregnancies, the effect of underlying causes of infertility, selection bias or confounding is unclear. In relation to adverse perinatal outcomes such as pregnancy loss, preterm birth and small for gestational age, increasing evidence suggests that multiple pregnancies explain much of the increased risk (Nelson and Lawlor, 2011; Lawlor and Nelson, 2012). Recent evidence from the European Surveillance of Congenital Anomalies (EUROCAT) suggests that a substantial proportion of associations with congenital anomalies may be due to underlying causes of infertility rather than ART per se (Davies et al., 2012; Levi Setti et al., 2016). However, these and studies of ART with longer-term offspring outcomes often rely on large-scale clinical and administrative datasets with minimal data on potential confounders. The use of longitudinal birth cohorts may be useful for assessing causal effects of ART or, more broadly, medically assisted reproduction on offspring health as they typically collect data on a range of potential confounders. The identification of associations of medically assisted reproduction with differential DNA methylation in genes that have established associations with health outcomes could be used to prioritize offspring disease outcomes for more detailed causal analyses that might be mediated by DNA methylation. Interrogating DNA methylation and its potential role as a mediating mechanism linking ART or, more broadly, medically assisted reproduction to health consequences in the offspring may provide insights into the biological pathways involved.

The aim of this study was to determine the association between having been conceived through medically assisted reproduction and genome-wide variation in cord blood DNA methylation at \( > 450 \) 000 CpG sites using the Illumina Methylation 450K BeadChip across multiple cohorts. Medically assisted reproduction is used here to describe the exposure studied as one of the cohorts included did not provide sufficient information for us to be certain the procedures were ART. Building on previous studies, we have used a multi-cohort approach with meta-analysis and replication, while interrogating the whole genome. We have also used functional analysis methods to attempt to characterize the biological implications of the findings in the context of long-term health outcomes.

**Materials and methods**

The overall approach to our methods was to pool results from epigenome-wide association studies (EWAS) in two general population birth cohorts, the Avon Longitudinal Study of Parents and Children (ALSPAC) and the Norwegian Mother, Father, and Child Birth Cohort (MoBa), as discovery analyses. We then explored replication of any discovery associations in an independent study, the ‘Clinical review of the Health of adults conceived following Assisted Reproductive Technologies’ (CHART) cohort.

**Study populations**

**Avon longitudinal study of parents and children (ALSPAC)**

ALSPAC is a population birth cohort that enrolled 14 541 pregnancies from residents in and around the city of Bristol in the South West of the UK with expected delivery dates between 1991 and 1992 (Boyd et al., 2013; Fraser et al., 2013). The study website contains details of all the data that is available through a fully searchable data dictionary and variable search tool: http://www.bristol.ac.uk/alspac/researchers/our-data/.

In ALSPAC, a subset of 1018 mother-offspring pairs had DNA methylation measured within the Accessible Resource for Integrated Epigenomics Studies (ARIES) (http://www.ariesepigenomics.org.uk/) (Relton et al., 2015). ALSPAC–ARIES participants were selected based on the availability of DNA samples at two time points for mothers and three time points for the offspring (Relton et al., 2015). After quality control checks and exclusion of multiple pregnancies, \( N = 857 \) pairs had reliable cord blood DNA methylation data to include in this study. After removing \( N = 21 \) participants without data about method of conception and a further \( N = 52 \) participants without all the covariates, we had a sample of \( N = 784 \) (77% of the original ARIES samples). In comparison to the overall ALSPAC cohort, the subset of ARIES mother–offspring pairs is slightly older, more likely to have a non-manual occupation and less likely to have smoked during pregnancy (Relton et al., 2015).

A second ALSPAC subset, the ALSPAC–Medically assisted reproduction (ALSPAC-MAR) subsample, also had cord blood DNA methylation measured. This subset consisted of additional ALSPAC participants selected to maximize the number of children conceived through medically assisted reproduction and hence increase power. One hundred seventy-eight infants conceived with medically assisted reproduction procedures, with cord blood samples, and 241 naturally conceived controls were selected for epigenome-wide DNA methylation analyses. The 241 naturally conceived participants were not a random sample but consisted of participants selected for other epigenetic studies that were run in the lab at the same time as the medically assisted reproduction cases (arthritis, diabetes, eating disorder, pre-eclampsia, hypertension, BMI, child autism and child undescended testicle). The distribution of these traits across the ALSPAC–MAR cases and control participants is shown in Supplementary Table S1. After removing those without all the covariates, there were \( N = 345 \) participants (82% of the additional subset; \( N = 155 \) cases and \( N = 190 \) non-controls). In both subsets of ALSPAC, information on the specific procedure used meant that we could not distinguish ART from the broader definition of medically assisted reproduction and hence for this cohort and in general in relation to exposure we use the latter term rather than ART. Written informed consent was obtained from all participants. The protocols and types of chip used for measurement of epigenome-wide DNA methylation were the same for both ALSPAC samples (Relton et al., 2015). Ethical approval for the ALSPAC data was granted by the ALSPAC law and ethics committee and local Research Ethics Committees. The details of the ethical approval at each stage of the study can be found in the ALSPAC website: http://www.bristol.ac.uk/alspac/researchers/research-ethics/.

**The Norwegian Mother and Child Cohort Study**

Participants represent two subsets of mother–offspring pairs from the national Norwegian Mother and Child Cohort Study (MoBa), a prospective population-based pregnancy cohort study conducted by the Norwegian Institute of Public Health (Magnus et al., 2006, 2016). The years of birth for MoBa participants ranged from 1999 to 2009 and the cohort includes more than 114 000 children, 95 000 mothers and 75 000 fathers. Two subsets of children also have cord blood DNA
methylation available. The two subsets are referred to here as MoBa1 and MoBa2. MoBa1 is a subset of a larger study within MoBa that includes a cohort random sample and newborns who developed asthma by age 3 years (Haberg et al., 2011), of which N = 1068 children had cord blood DNA methylation available after quality control exclusions (Joubert et al., 2012). MoBa2 consists of a further 685 participants who were also a random cohort sample and newborns who developed asthma that was still present at age seven (157 with asthma) (Reese et al., 2019). MoBa2 participants did not overlap with those in MoBa1 and the protocol and type of chips used for DNA methylation analyses were the same in both subsets. Cord blood DNA methylation data after quality control exclusions were available in N = 680 MoBa2 children. MoBa1 and MoBa2 data were pooled together and N = 1518 (22 conceived by ART) of these had data on ART and all the covariates included in the analysis.

Ethical approval for MoBa data was granted by Regional Committee for Ethics in Medical Research of South/East Norway, the Norwegian Data Inspectorate, and the Institutional Review Board of the National Institute of Environmental Health Sciences. Written informed consent was obtained from all MoBa participants.

Medically assisted reproduction assessment

ALSPAC participants were sent a postal questionnaire at 12 weeks gestation that asked a two-part question: (i) 'Did you use any treatments to help conceive this pregnancy?', a binary yes/no response, and (ii) 'If yes which one?', a text answer. We used the first question to create a binary variable for the main analysis. We used the text response to the second question to perform a sensitivity analysis where the medically assisted reproduction category included only mothers who responded having used ART (IVF or gamete intrafallopian transfer), IUI, or OI by hormones, whilst excluding those who reported using male infertility treatments, natural monitoring, other fertility treatments, other treatment (not fertility), no treatment or unknown and those with mismatches between the two questions (N = 7 removed in ALSPAC–ARIES and N = 28 removed in ALSPAC–MAR).

In MoBa, ART information was obtained from the medical birth registry. The notification form completed by the midwife attending the delivery indicated whether the pregnancy was conceived by IVF, ICSI or other/unknown ART methods, as a single response.

DNA methylation

In the ALSPAC-ARIES and ALSPAC-MAR subsamples, DNA was extracted from previously collected and frozen cord blood. DNA was then bisulphite converted using Zymo EZ DNA MethylationTM kit (Zymo, Irvine, CA, USA) and methylation was measured at 485 512 CpG sites using the Illumina Infinium HumanMethylation450 BeadChip assay according to manufacturers’ protocols (Relton et al., 2015). The methylation arrays were scanned with an Illumina iScan and the initial quality was checked with GenomeStudio (version 2011.1). The methylation data pre-processed using minfi package (Min et al., 2018). The process included quantile normalization and quality checks such as sex chromosomes mismatches and genotype mismatches.

In MoBa1, umbilical cord blood samples were collected and frozen at birth at −80°C. All biological material was obtained from the Biobank of the MoBa study (Paltiel et al., 2014). Bisulphite conversion was performed using the EZ-96 DNA Methylation kit (Zymo Research Corporation, Irvine, CA, USA) and DNA methylation was measured at 485 577 CpGs in cord blood using the Illumina Infinium HumanMethylation450 BeadChip array (Joubert et al., 2012). Raw intensity (.idat) files were handled in R using the minfi package to calculate the methylation level at each CpG as the beta-value and the data were exported for quality control and processing. Similar sample specific quality control was performed in MoBa1 and MoBa2, as follows: control probes (N = 65) and probes on X (N = 11 230) and Y (N = 416) chromosomes were excluded in both datasets. Remaining CpGs missing > 10% of methylation data were also removed (N = 20 in MoBa1, none in MoBa2). Samples indicated by Illumina to have failed or have an average detection P-value across all probes < 0.05 (N = 49 MoBa1, N = 35 MoBa2) and samples with gender mismatch (N = 13 MoBa1, N = 8 MoBa2) and GWAS outliers (N = 6 MoBa1, N = 4 MoBa2) were also removed. For MoBa1 and MoBa2, we accounted for the two different probe designs by applying the intra-array normalization strategy Beta Mixture Quantile dilation (BMQ) (Bibikova et al., 2011). After quality control exclusions, the sample sizes of the cord blood DNA methylation data (including with missing conception data and covariates) were 1056 for MoBa1 and 680 for MoBa2. To account for differences between MoBa1 and MoBa2, we also adjusted for the different design variables, such as sample pull or selection factors (MoBa2) with a fixed effect variable.

EWAS meta-analysis

We estimated the association between medically assisted reproduction and cord blood DNA methylation at all the CpGs that passed QC in ALSPAC–ARIES, ALSPAC–MAR and MoBa by running linear regression models of medically assisted reproduction (exposure) on DNA methylation (outcome) using the CpGassoc package in R (Barfield et al., 2012). To control for batch, we included a term for bisulphite treatment plate. We used an algorithm and a reference panel that is suitable for cord blood (Bakulski et al., 2016) to calculate cell type composition and added estimated cell counts as covariates. Additionally, we adjusted for infant sex at birth and potential confounding by maternal age at delivery, maternal BMI and maternal smoking during the first trimester of pregnancy. In ALSPAC, maternal pre-pregnancy weight, height and smoking were obtained through self-report in questionnaires completed in the first trimester of pregnancy whereas maternal age at delivery and infant sex were extracted from obstetric records. Smoking during the first trimester was categorized into a binary variable of 'Did not smoke’ and ‘Smoked’. In MoBa, for both datasets, information maternal pre-pregnancy weight height and smoking was obtained through self-report questionnaires completed at around 17 weeks of gestation; maternal age at delivery and infant sex were obtained from the birth registry records. Smoking was categorized in a three-level variable, ‘non-smoker’, ‘stopped early in pregnancy’ and ‘smoked throughout pregnancy’.

A meta-analysis of the summary statistics of the EWAS results from each study sample (ALSPAC–ARIES, ALSPAC–MAR and MoBa) was carried out using METAL (version 2011-03-25) (Willer et al., 2010), using a fixed effects model with inverse variance weighting (Rice et al., 2018). Since in the MoBa EWAS the X and Y chromosome were omitted, the meta-analysis excluded CpGs on these chromosomes.
Replication in an independent cohort
We sought replication of results for all CpG sites with $P_{\text{FDR}} < 0.05$ in the meta-analysis EWAS in an independent study sample, the ‘Clinical review of the Health of adults conceived following Assisted Reproductive Technologies’ (CHART) cohort. CHART is an Australian cohort of $N = 547$ adults conceived by IVF and $N = 549$ naturally conceived controls (Lewis et al., 2017). In a subsample of $N = 193$ ART-conceived and $N = 86$ non-ART adults who gave their consent for epigenetic analyses, DNA methylation was measured in DNA isolated from neonatal blood spots (Guthrie spots) that were collected at 2–3 days after birth using the Illumina Infinium MethylationEPIC BeadChips array. Pre-processing was carried out using MissMethyl and minfi R packages and normalization was performed using SWAN (Maksimovic et al., 2012). Quality checks involved the exclusion of samples with mean detection $P$-value $> 0.01$, probes with detection $P$-value $> 0.01$, those associated with SNPs and cross-reactive probes. Cell composition was estimated using the Bakulski cord blood cell reference method (Bakulski et al., 2016). Linear regression modelling was performed using limma R package and included sample plate, cell proportions (six cell types), infant sex and maternal age at delivery covariates (data were not available in this study to adjust for potential confounding by maternal pre-pregnancy BMI or pregnancy smoking). After quality control exclusions, there were 146 ART cases and 58 controls with data on ART and covariates to use in this analysis. Ethical approval for the CHART study was granted by the Royal Children’s Hospital Human Research Ethics Committee (RCH HREC Project 33163). All participants for this study gave written informed consent.

Biological characterisation
CpG sites associated with medically assisted reproduction were compared to those listed in the EWAS catalogue (http://www.ewascatalog.org/) in July 2019. Studies indexed by the EWAS catalogue included at least 100 000 CpG sites in analyses and had sample sizes of at least 100 individuals.

Gene ontology (GO) enrichment (Ashburner et al., 2000; The Gene Ontology Consortium, 2017) for the first 100 CpG sites from the meta-EWAS ranked by ascending $P$-value was conducted using the R package missMethyl (Phipson et al., 2016). This method takes into account the differing number of probes per gene found on the array which can otherwise bias results (Geelheer et al., 2013). Since hyper- and hypo-methylation at CpG sites in our analysis were likely to be biologically distinct we stratified our enrichment analysis accordingly.

Enrichment analyses were conducted using the R package LOLA (Sheffield and Bock, 2016). Input was genomic coordinates of the first 100 CpG sites from the meta-EWAS ranked by ascending $P$-value and the background set was the genomic coordinates all array CpG sites included in the meta-EWAS. The LOLA core region set was used to test for enrichments. As above, sites were stratified into hyper- and hypo-methylated CpG sites. For each LOLA analysis, we filtered results retaining enriched region sets only when the support (i.e. number of regions overlapping) $> 5$ and the $q$-value was $< 0.05$.

To further identify enrichment of CpG sites associated with medically assisted reproduction at cell type-specific histone modifications and DNaseI hypersensitivity sites (DHS) we used eFORGEv2.0 (Breeze et al., 2016). H3 marks and DHS were analysed from the consolidated Roadmap Epigenomics data set. Input was the first 100 CpG sites from the EWAS when ranked by ascending $P$-value. The background set of CpG sites was all CpG sites on the array analyzed in the meta-EWAS. As above, sites were stratified into hyper- and hypo-methylated CpG sites.

The genes mapped to the CpGs associated with medically assisted reproduction at $P_{\text{FDR}} < 0.05$ and in DMRs were searched for published associations in the GWAS catalogue (https://www.ebi.ac.uk/gwas/, v1.0.2: 04 June 2020, last date accessed) (Buniello et al., 2019).

Methylation quantitative trait loci analysis
For each CpG associated with medically assisted reproduction in the single-site EWAS at $P_{\text{FDR}} < 0.05$, we searched for methylation quantitative trait loci (mQTLs) in the mQTL database (www.mqtldb.org, 10 June 2020, last date accessed) (Gaunt et al., 2016).

Results

Study sample characteristics
The characteristics of the study participants for ALSPAC–ARIES, ALSPAC-MAR and MoBa are shown in Table I and Supplementary Table SII. ALSPAC-MAR and MoBa included a higher proportion of smokers during the first trimester and female offspring compared to ALSPAC-ARIES. Mean birthweight, gestational length and maternal pre-pregnancy BMI were similar across the three study samples. In all three samples, mothers of infants conceived via medically assisted reproduction were older and in ALSPAC-MAR and MoBa infants conceived with medically assisted reproduction were slightly more likely to be female. In ALSPAC-MAR, and to a weaker extent ALSPAC–ARIES, mothers of infants conceived with medically assisted reproduction were less likely to smoke and had lower BMI, which may reflect UK guidelines that restrict some ART procedures to women with a healthy BMI and who do not smoke at the time of treatment.

EWAS meta-analysis
Figure 1 and Table II summarize the results of the EWAS meta-analysis adjusted for gender at birth, maternal age at delivery, maternal BMI and maternal smoking during pregnancy. There were five CpG sites associated with medically assisted reproduction at the genome-wide level ($P_{\text{FDR}} < 0.05$), four of which surpassed the threshold for Bonferroni corrected $P$-values ($P_{\text{Bonferroni}} < 0.05$). These were hyper-methylated sites. The effect sizes were lower than 1% absolute difference in methylation between the two groups. The direction of effect was concordant across studies for three of the five sites and it was concordant for four of the five sites between the two ALSPAC subsamples. Three of the CpG sites were located in known genes, including two sites that were annotated to the same gene coding for arrestin domain-containing protein 1 ($ARRDC4$). In all three study samples methylation at $ARRDC4$ was $<1\%$ higher in ART cases compared to non-ART controls at unadjusted $P$-value $< 0.05$.

EWAS sensitivity analyses conducted in ALSPAC–ARIES and ALSPAC-MAR with restriction to participants who reported specific forms of medically assisted reproduction (IVF, intratuterine insemination, or OI by hormones) and adjusted for the same covariates as the main analysis showed similar results to the main analyses with high
correlation between the regression beta coefficients ($R^2 = 0.86$ for ALSPAC–ARIES and $R^2 = 0.95$ for ALSPAC–MAR).

Further sensitivity analyses conducted by MAR procedure within the ALSPAC subsamples (where there were enough cases to run the analysis) showed associations with OI by hormones for all CpGs and intrauterine insemination for cg18529845 (Supplementary Fig. S1).

### Replication in CHART

In the CHART sample, there was no clear evidence of association at any of the 5 CpG sites identified in the discovery meta-analysis (Supplementary Table SIII).

### Biological characterisation

Three of five sites associated with medically assisted reproduction at genome-wide level in our discovery sample were previously reported to be associated with other phenotypes according to the EWAS catalogue (see Supplementary Table SIV). cg18529845 and cg17855264 were associated in multiple EWAS studies of cancer, ageing and HIV infection. cg24051276 was associated with rheumatoid arthritis, dementia and palsy.

No GO terms were shown to be enriched after accounting for multiple testing. In the hypermethylated probe set the most highly enriched terms were biological processes linked to modulation by host of viral process and androgen metabolism (see Supplementary Table SV).

To identify enrichment of sites associated with medically assisted reproduction within gene and gene regulatory regions we utilized eFORGE and LOLA. Using LOLA, enrichment was identified amongst hypermethylated CpGs and intrauterine insemination for cg18529845 (Supplementary Fig. S1).

eFORGE was used to identify cell type specific DHS in tissues profiled by the NIH Roadmap Epigenomics consortium (see Supplementary Table SVII). Enrichment was observed for the hypermethylated set. The strongest enrichment identified for DHS was found in embryonic stem cells. The histone modifications H3K9me3 and H3K9me1 were strongly enriched in multiple tissues, including embryonic stem cells, blood, ovary, stem and foetal cells. H3K9me3 is associated with decreased accessibility of chromatin and is pivotal in lineage commitment during organogenesis and for maintaining cell lineage in differentiated cells (Nicetto et al., 2019). H3K4 methylation was also identified using LOLA and is typically detected in promoter regions of active genes (Barski et al., 2007).

The ‘GWAS Catalogue’ search showed that a genetic variant in SRD5A2, whose methylation was associated with medically assisted reproduction, had previously been found to be associated with male baldness (Supplementary Table SVIII).

### mQTL analysis

To explore the potential health consequences of medically assisted reproduction, we searched for cis-mQTLs of the top five CpGs from the meta-analysis by looking at SNPs associated with the CpGs in the mQTLdb database (www.mqtldb.org). We were not able to identify any suitable mQTL from this analysis as all the SNPs associated with the five top CpGs were located in trans (>1 kb from the CpG site).

### Discussion

We conducted an EWAS meta-analysis of the association of medically assisted reproduction with cord blood DNA methylation across two European birth cohorts, ALSPAC and MoBa. The results showed evidence of an association between medically assisted reproduction and DNA methylation at five CpG sites. By interrogating online databases, we also found evidence that some of the methylation differences associated with medically assisted reproduction were associated with diseases and health-related traits in adulthood. At the molecular level, hypermethylation linked to medically assisted reproduction occurred in regulatory sites involved in chromatin remodelling. However, we could not confirm whether the associations of medically assisted reproduction with cord blood DNA methylation are causal.

---

Table I Characteristics of the three study samples used in the epigenome-wide association studies meta-analysis.

<table>
<thead>
<tr>
<th></th>
<th>ALSPAC-ARIES</th>
<th>ALSPAC-MAR</th>
<th>MoBa</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N = 784</td>
<td>N = 345</td>
<td>N = 1518</td>
</tr>
<tr>
<td>ART (%)</td>
<td>--</td>
<td>--</td>
<td>22 (1.5)</td>
</tr>
<tr>
<td>Medically assisted reproduction (%)</td>
<td>28 (3.6)</td>
<td>155 (44.9)</td>
<td>--</td>
</tr>
<tr>
<td>Smoked first trimester (%)</td>
<td>100 (12.8)</td>
<td>83 (24.1)</td>
<td>415 (27.3)</td>
</tr>
<tr>
<td>Offspring gender at birth (% female)</td>
<td>398 (50.6)</td>
<td>143 (41.4)</td>
<td>706 (46.5)</td>
</tr>
<tr>
<td>Maternal age (years) (mean (SD))</td>
<td>29.65 (4.41)</td>
<td>28.84 (4.83)</td>
<td>29.96 (4.31)</td>
</tr>
<tr>
<td>Maternal BMI (kg/m²) (mean (SD))</td>
<td>22.92 (3.80)</td>
<td>24.52 (6.57)</td>
<td>24.12 (4.32)</td>
</tr>
<tr>
<td>Birthweight (g) (mean (SD))</td>
<td>3419 (481)</td>
<td>3364 (606)</td>
<td>3648 (541)</td>
</tr>
<tr>
<td>Gestational age (weeks) (mean (SD))</td>
<td>39.70 (1.48)</td>
<td>39.33 (1.86)</td>
<td>39.48 (1.61)</td>
</tr>
</tbody>
</table>

ALSPAC, Avon Longitudinal Study of Parents and Children; ARIES, Accessible Resource for Integrated Epigenomics Studies; MAR, Medically Assisted Reproduction; MoBa, Norwegian Mother, Father, and Child Birth Cohort.

---

Laugesen et al. (2019).
reproduction with differential methylation at the strongest five CpGs were causal (or might be explained by confounding, including by the underlying pathology resulting in infertility). Nor could we establish whether the methylation changes were causally linked to diseases and health-related traits using Mendelian randomization.

Several previous studies have explored differential DNA methylation in infant blood cells related to conception by ART using either candidate or EWAS approaches. Most of these have had smaller sample sizes than our study and/or have not sought replication in an independent group. In a recent study conducted on the CHART cohort used

---

**Figure 1.** Association between cord blood DNA methylation and medically assisted reproduction estimated by the meta-analysis. (a) Quantile-quantile plot of the observed versus expected distribution of P-values; (b) volcano plot of the P-values versus the beta coefficients. \( \lambda \) = genomic inflation factor calculated using the median method. (c) Manhattan plot of the distribution of P-values across chromosomes.

---

**Table II Results of the epigenome-wide association study meta-analysis (CpG sites at \( P_{\text{FDR}} < 0.05 \)).**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Chromosome Position</th>
<th>Beta Regression Coefficient</th>
<th>SE</th>
<th>( P_{\text{FDR}} )</th>
<th>( P_{\text{Bonferroni}} )</th>
<th>Meta-analysis Study-specific results</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARID4C</td>
<td>15</td>
<td>145.051,726</td>
<td>0.23</td>
<td>0.003</td>
<td>0.007</td>
<td>ARIES MoBa ALSPAC-MAR</td>
</tr>
<tr>
<td>ARID4C</td>
<td>15</td>
<td>985.039.5</td>
<td>0.47</td>
<td>0.007</td>
<td>0.007</td>
<td></td>
</tr>
<tr>
<td>ARID4C</td>
<td>15</td>
<td>371.936.36</td>
<td>0.31</td>
<td>0.007</td>
<td>0.007</td>
<td></td>
</tr>
<tr>
<td>ARID4C</td>
<td>15</td>
<td>985.394.7</td>
<td>0.28</td>
<td>0.007</td>
<td>0.007</td>
<td></td>
</tr>
<tr>
<td>ARID4C</td>
<td>15</td>
<td>85.713.421</td>
<td>0.41</td>
<td>0.007</td>
<td>0.007</td>
<td></td>
</tr>
<tr>
<td>ARID4C</td>
<td>15</td>
<td>85.297.945</td>
<td>0.41</td>
<td>0.007</td>
<td>0.007</td>
<td></td>
</tr>
</tbody>
</table>

Beta regression coefficients are reported as percent difference in methylation between groups.

FDR, False discovery Rate; ALSPAC, Avon Longitudinal Study of Parents and Children; ARIES, Accessible Resource for Integrated Epigenomics Studies; MAR, Medically Assisted Reproduction; MoBa, Norwegian Mother, Father, and Child Birth Cohort.
as replication in our study (Novakovic et al., 2019), 18 CpG sites were associated with ART, 9 of which were available in our study. In our meta-analysis, at four of these nine CpGs the direction of the effects was concordant (including at CHRNE) and with low P-values (0.07–0.006) (Supplementary Table SIX), thus, providing some evidence of consistency across studies, although none of these nine CpGs had P-values < 0.006 (P = 0.05 Bonferroni-corrected to take into account nine multiple comparisons). Differences between our study and this one may be explained by differences in the adjustment for confounding factors (we adjusted for batch, cell-type, maternal pre-pregnancy BMI, pregnancy smoking, age at delivery and infant sex, whereas the published study adjusted for batch, cell-type and infant sex), the different sample used (blood in our study and Guthrie spots in the published study) and/or differences in the cases definition (broad range of treatments and self-reported in our study, whereas restricted to ART and from hospital records in the published study). The results in the published study are more generally related to ART (which involves OI as part of the procedure and in vitro manipulation processes), whereas the associations reported in our study seems to be specific for procedures that did not involve in vitro gamete or embryo manipulation (OI and intrauterine insemination). However, given that the two studies were broadly similar in population, analysis methods and size, the lack of consistency between the two may be because the findings in both studies are due to chance and do not reflect real replicable associations. This would be consistent with the lack of replication of our findings in the CHART study.

Most of the CpGs identified in this study are located in the proximity of known genes. We found evidence of hypermethylation at the transcription start site of the SRS52A2 gene, coding for steroid S-alpha Reductase 2, an enzyme involved in androgen metabolism and male sexual development. Hypermethylation at this site was associated particularly with OI and intrauterine insemination, suggesting a specific effect of hormonal stimulation, gamete manipulation, and/or freezing and thawing of eggs or sperm. Since our study is observational, we cannot rule out that an impairment in this gene at the parental level was present before having received the medical procedures to help conceiving rather than their consequence and could be related to parental sub-fertility rather than the fertility procedures per se. The lack of association in the replication sample at this and the other sites that were differentially methylated in our discovery sample may be due to the different sample collections (cord blood in our discovery meta-analysis and Guthrie dry blood spots collected at 2–4 days in CHART). They could also be due to heterogeneity in the cases definition between cohorts. In CHART, only those conceived by IVF, ICSI or, in a minority of cases, other ART were included in the cases and this was obtained from hospital records. However, the most likely interpretation is that these additional associations are driven by chance.

Our study has several strengths compared to other previously published studies. By combining participants from different studies, we have achieved a larger sample size. We also adjusted for potential confounding maternal characteristics (maternal pre-pregnancy BMI, pregnancy smoking and age at delivery), whereas most previous studies had either smaller sample sizes or adjusted for fewer confounders. Maternal BMI, smoking and age are associated with low fertility as well as DNA methylation and including these factors is important as it partially controls for confounding due to infertility. We also conducted extensive biological characterisation using freely available databases and an mQTL look-up to attempt to determine potential causal links to disease and health-related traits. Finally, we explored replication in an independent sample.

This study has also some limitations. First, our definition of MAR is heterogeneous. OI by hormones, is often used in combination with IVF and intrauterine insemination. Therefore, it is challenging to separate the effects of hormone stimulation from those of in vitro culturing. In our discovery meta-analysis our main exposure was self-reported assisted reproduction and, although we could explore in ALSPAC the effects of OI and intrauterine insemination, the IVF groups had very small sample sizes. In ALSPAC, participants were asked a very general question about having used any treatment to help them conceive and then had the opportunity to provide additional information in a text response. In MoBa, the data were obtained from the birth register, but the report was a single entry completed by a midwife that asked whether the conception was by ART (defined as IVF, ICSI or other ART) so we were unable to explore the specific effect of different procedures. Despite our meta-analysis approach, case numbers in each cohort are small and this limitation should be addressed in future studies. Another limitation is that due to the observational nature of the study it has not been possible to establish causality between medically assisted reproduction and offspring DNA methylation. Even though we adjusted for potential confounders the possibility of residual confounding, for example by paternal sub-fertility, remains. Furthermore, due to an insufficient number of mQTLs, our study did not provide the opportunity to conduct Mendelian randomization to explore causal effects between methylation and disease risk.

Overall, we show that newborns conceived by medically assisted reproduction present with altered DNA methylation in cord blood white cells. However, we cannot distinguish whether these methylation profiles are due to the actual fertility treatments, reflect the underlying causes of subfertility, or are chance associations. If any are causal, we do not know whether there are long-term consequences for offspring health. As this is one of the largest studies to date, has adjusted for confounders and tried to explore replication, it highlights the need for larger studies and/or attempts to harmonize data across all studies and undertake a larger collaborative effort. There is also a need for studies with more detailed information on the type of fertility treatment, and on the cause of parental sub-fertility. However, to the best of our knowledge, studies with such detailed exposure information and DNA methylation in large numbers are currently lacking. Additional follow-up studies with DNA methylation at older ages would also be useful to investigate a potential resolution of DNA methylation variation associated with fertility treatments over time as indicated by the CHART study (Novakovic, et al., 2019). Current efforts in generating more mQTL databases such as the GoDMC consortium (http://www.godmc.org.uk/) might provide additional mQTL for use in Mendelian randomisation to establish causal links between differential DNA methylation related to medically assisted reproduction and future disease risks.

**Supplementary data**

Supplementary data are available at Human Reproduction online.
Data availability

The data underlying this article cannot be shared publicly for the privacy of individuals that participated in the study. The data will be shared on reasonable request to the individual cohorts. For ALSPAC, data are available according to the procedures listed at http://www.bristol.ac.uk/alspac/researchers/access/. For MoBa, data can be requested at https://www.fhi.no/en/studies/moba/free-formaterialer/researcher-access/.

Acknowledgements

ALSPAC: The authors are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. This publication is the work of the authors and Doreetta Caramaschi will serve as guarantor for the contents of this paper. The Norwegian Mother, Father and Child Cohort Study: The authors are very grateful to all the participating families in Norway who take part in this ongoing cohort study.

Authors’ roles

D.C., J.J. and H.R.E.: data analysis, interpretation of results and manuscript preparation; C.M.P. and B.N.: data analysis and draft revisions; R.S., J.H. and S.J.L.: data acquisition and draft revision; S.L.: Data analysis, draft revisions. M.C.M.: Data analysis, draft revisions, and critical input. S.E.H.: Data acquisition, draft revisions, final draft; D.A.L. and C.L.R.: conception/design of the work, data acquisition, interpretation of results and draft revisions. All authors provided critical input on the manuscript.

Funding

This study has also been supported by the US National Institute of Health (R01 DK10324), the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007-2013/) ERC Grant agreement no. 669545, European Union’s Horizon 2020 research and innovation programme under Grant agreement no. 733206 (LifeCycle) and the NIHR Biomedical Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). Methylation data in the ALSPAC cohort were generated as part of the UK BBSRC funded (BB/702575/1 and BB/025263/1) Accessible Resource for Integrated Epigenomic Studies (ARIES, http://www.ariesepigenomics.org.uk). ALSPAC GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. D.C., J.J., C.L.R. D.A.L and H.R.E. work in the MRC Integrative Epidemiology Unit at the University of Bristol, supported by the UK Medical Research Council and the University of Bristol (Grant nos. MC_UU_00011/1, MC_UU_00011/5, MC_UU_00011/6). B.N. is supported by an NHMRC (Australia) Investigator Grant (1173314). The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research, NIH/NIHEHS (Contract no N01-ES-55558), NIH/NINDS (Grant nos. (i) U01 NS047537-01 and (2) U01 NS 47537-06A1). For this work, MoBa 1 and 2 were supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES-49019) and the Norwegian Research Council/BIOBANK (Grant no. 221097). This work was partly supported by the Research Council of Norway through its Centres of Excellence funding scheme, project number 262700.

Conflict of interest

D.A.L. has received support from national and international government and charity funders, as well as from Roche Diagnostics and Medtronic for research unrelated to this study. All other authors declare no conflict of interest.

References


Chen M, Heilbronn LK. The health outcomes of human offspring conceived by assisted reproductive technologies (ART). *J Dev Orig Health Dis* 2017; **8**:388–402.


